BCR and pachyonychia congenita: PSCA expression has shown been to correlate with the disease characteristics of PC (e.g., advanced tumor stage and high Gleason score) and with post-treatment clinical outcomes (e.g., progression to androgen-independent disease, local invasion, BCR, and bone metastases) [7, 24, 25].